Ardelyx (ARDX) delivered earnings and revenue surprises of 33.33% and 40.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Big data is a sham. For years now, we have been told that every company should save every last morsel of digital exhaust in some sort of database, lest management lose some competi...Ardelyx, Inc. (Nasdaq: ARDX) announced the resignation of Dr. Geoffrey Block from the Board of Directors after nearly five years of service. Dr. Block is the Associate Chief Medical Director and Senior Vice President of Clinical Research and Medical Affairs at U.S. Renal Care. The company expressed gratitude for Dr. Block's contributions and highlighted his role in Ardelyx's evolution from a ...Track ABVC BioPharma Inc (ABVC) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsSee Ardelyx, Inc. (ARDX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Ardelyx's cash and investment position at the end of September increased to $165 million after Q2 income of $6.6 million, signifying the company borrowed at least $22.5 million from SLR. It is a ...Stock Ideas. Long Ideas. Healthcare. Ardelyx: Final Countdown Begins. May 18, 2023 9:17 AM ET Ardelyx, Inc. (ARDX) Stock 63 Comments. 14 Likes. Clinically …ARDX. Net Product Sales Revenue: IBSRELA generated $80.1 million in 2023, with Q4 showing a 26% increase over Q3. 2024 Revenue Forecast: Ardelyx projects IBSRELA sales to reach between $140.0 to ...Ardelyx, Inc. (Nasdaq: ARDX) reported $45.6 million in Q1 product-related revenue, with $28.4 million from IBSRELA and $15.2 million from XPHOZAH. The company ended Q1 with around $203 million in cash and investments. Ardelyx saw significant growth in net product sales revenue for both IBSRELA and XPHOZAH, with plans to expand market position.Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update. Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH. 19 days ago - GlobeNewsWire.Ardelyx (ARDX) delivered earnings and revenue surprises of 500% and 59.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?Based on the most recent data, ARDX has returned 44.7% so far this year. Meanwhile, the Medical sector has returned an average of 5.3% on a year-to-date basis. This means that Ardelyx is ...Greater Boston 400 Fifth Avenue, Suite 210 Waltham, MA 02451 Bay Area 34175 Ardenwood Boulevard Fremont, CA 94555By year 2025 revs could be ramping up between $300K - $0.5B. But an offering in this case is not a bad thing to support on going R&D. The more cash they are sitting only makes the company stronger in this case. Any lowball offer will be instantly rejected. BP loves lowballing companies on the verge of going belly up.All debt owed by the company, including both long-term and short-term debt. This does not include accounts payable and similar liabilities, but may include leases depending on the analysis. $34 ...Shares of Ardelyx (ARDX Quick Quote ARDX - Free Report) were up 41% on Nov 17 after management announced thatan FDA Advisory Committee recommended approving the company’s new drug application ...Track reAlpha Tech Corp. (AIRE) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTrack Cardio Diagnostics Holdings Inc (CDIO) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsArdelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations.Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.XPHOZAH, discovered and developed by Ardelyx, is a first-in-class, phosphate absorption inhibitor with a differentiated mechanism of action that acts locally in the gut to inhibit the sodium ...View the latest Ardelyx Inc. (ARDX) stock price, news, historical charts, analyst ratings and financial information from WSJ.Ardelyx, a publicly traded company on the NASDAQ under the ticker symbol ARDX, has just released its financial results for the second quarter of 2022. Best stocks to buy now ContactAug 2, 2023 · Ardelyx, a publicly traded company on the NASDAQ under the ticker symbol ARDX, has just released its financial results for the second quarter of 2022. Best stocks to buy now ContactComplete Ardelyx Inc. stock information by Barron's. View real-time ARDX stock price and news, along with industry-best analysis.Ardelyx Inc • Biotechnology Wed 22 May, close Current 1 day ago 2 days ago 3 days ago 4 days ago 5 days ago 6 days ago 7 days ago 8 days ago 9 days ago 10 days ago 11 days ago 12 days ago 13 days ago 14 days ago 15 days ago 16 days ago 17 days ago 18 days ago 19 days ago 20 days ago 21 days ago 22 days ago 23 days ago 24 days ago 25 days agoArdelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and …At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.TipRanksIn the last reported quarter, Ardelyx’s product revenues from the sale of Ardelyx amounted to $4.9 million, signifying a sequential growth in revenues of 206.25%. We expect the product to have ...Ardelyx stock has received a consensus rating of buy. The average rating score is and is based on 19 buy ratings, 3 hold ratings, and 0 sell ratings. What was the 52-week low for Ardelyx stock?WALTHAM, Mass., Feb. 24, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq:ARDX), a biopharmaceutical company founded with a mission to discover, develop... WALTHAM, Mass., Feb. 24, 2022 ...View Ardelyx, Inc. ARDX stock quote prices, financial information, real-time forecasts, and company news from CNN.Find the latest news headlines from Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.3 days ago · Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update. Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH. 19 days ago - GlobeNewsWire.Your lens into the world of crypto. See all Stocktwits emails. The latest messages and market ideas from James Johnston (@Johnstonj27) on Stocktwits. 50 years old, live out in Wildomar California, Grew up in Laguna Niguel and lived in Huntington Beach. Swing Trader and a test rider for Kawasaki Motors Corp.9 equities research analysts have issued 1-year price targets for Ardelyx's stock. Their ARDX share price targets range from $8.50 to $15.00. On average, they predict the company's stock price to reach $12.81 in the next year. This suggests a possible upside of 68.4% from the stock's current price.395 subscribers in the ARDELYX community. The selective sodium hydrogen exchanger 3 (NHE3) inhibitor Tenapanor is being developed by Ardelyx Inc for…Investors & Media. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Ardelyx’s financial performance into perspective. Volume: Today's Open: Previous Close: Data Provided by Refinitiv.Stock analysis for Ardelyx Inc (ARDX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company ...The Ardelyx stock price fell by -2.65% on the last day (Tuesday, 21st May 2024) from $7.93 to $7.72. During the last trading day the stock fluctuated 3.19% from a day low at $7.69 to a day high of $7.94. The price has fallen in 6 of the last 10 days and is down by -17.08% for this period. Volume fell on the last day along with the stock, which ...A list of the latest Ardelyx Inc News - ARDX Stock News, Press Releases, Earnings Report, Financial Disclosures, Offerings, Acquisitions.To access the live webcast of Ardelyx's session, please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be ...Ardelyx’s first approved product, IBSRELA® (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis, which has completed three successful Phase 3 trials.Ardelyx ( NASDAQ: ARDX) is scheduled to announce Q1 earnings results on Wednesday, May 3rd, after market close. The consensus EPS Estimate is -$0.10 and the consensus Revenue Estimate is $10.41M ...From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to create targeted, first ...WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Track Tenax Therapeutics Inc (TENX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsArdelyx Reports First Quarter 2024 Financial Results and Provides Business Update. Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH. 19 days ago - GlobeNewsWire.Find the latest news headlines from Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.Aug 2, 2023 · Ardelyx (ARDX) delivered earnings and revenue surprises of 33.33% and 40.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Meta's surveillance business model is facing an interesting legal challenge in the U.K. Meta’s surveillance-based business model is facing an interesting legal challenge in the U.K...Ardelyx, Inc. (NASDAQ:ARDX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. Consensus estimates suggest investors ...Track BioCardia Inc. (BCDA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsHere is how Ardelyx (ARDX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart ...Find the latest Ardelyx, Inc. (ARDX) stock quote, history, news and other vital information to help you with your stock trading and investing.Nachrichten zur ARDELYX Aktie - schnell & kompetent - Aktuelle TOP-Meldung: Ardelyx: Quartalsergebnisse zum jüngsten JahresviertelArdelyx, a publicly traded company on the NASDAQ under the ticker symbol ARDX, has just released its financial results for the second quarter of 2022. Best stocks to buy now ContactArdelyx, Inc. Reports Employment Inducement Grants. WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 6, …